Nordics Pharma Snapshot 2020
A selection of data on the Nordic pharma markets (Denmark, Finland, Iceland, Norway, and Sweden), including market value, R&D spend, production,…
Tagged with R&D and Clinical Trials
European Medicines Agency (EMA) Advanced Therapy Medicinal…
A full list of EMA ATMP approvals.
Made with Visme Infographic Maker
US FDA Approved Cell & Gene Therapy Products
A full list of the cell and gene therapy products approved by the US FDA.
Made with Visme Infographic Maker
Japanese PMDA Regenerative Medicine Approvals
A full list of the regenerative medicine products that have been approved by the PMDA, Japan’s drug regulatory body. Made with Visme…
US FDA New Drug Approvals 2019 Snapshot
Annual numbers of new molecular entities (NMEs) and biologics license applications (BLAs) approved by the FDA’s Center for Drug Evaluation and…
EMA Drugs Approved in 2019
An overview of the types of new medicines recommended for approval by the European Medicines Agency (EMA) in 2019. Made with Visme Infographic Maker…
UK Biotech Snapshot 2019
A new report from the UK BioIndustry Association (BIA) asserts that the UK biotech industry is booming, despite Brexit uncertainties. Financing…
France Pharma Snapshot 2019
A snapshot of the latest data on the French pharmaceutical industry from industry association LEEM, including market revenues, R&D investments,…
Czech Republic Pharma Snapshot 2019
Czech Republic’s overall pharma market value increased 5 per cent in 2019, while its units produced decreased by 1 per cent. Made with…
Central & Eastern Europe Pharma Market Snapshot
Poland is by far the largest pharma market in the Central and Eastern Europe (CEE) region, with a total value of EUR 6.352 billion for 2017. The Czech…
Taiwan Clinical Trials Snapshot
An overview of all clinical trials conducted in Taiwan between 2011 and 2017. Made with Visme Infographic Maker The number of clinical…
Alzheimer’s Disease R&D Expenditure Snapshot 2019
Alzheimer’s drugs represent a high-risk, high-reward proposition for global pharma. As David H. Crean recently wrote for PharmaBoardroom,…
